JP2015532096A5 - - Google Patents

Download PDF

Info

Publication number
JP2015532096A5
JP2015532096A5 JP2015534771A JP2015534771A JP2015532096A5 JP 2015532096 A5 JP2015532096 A5 JP 2015532096A5 JP 2015534771 A JP2015534771 A JP 2015534771A JP 2015534771 A JP2015534771 A JP 2015534771A JP 2015532096 A5 JP2015532096 A5 JP 2015532096A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
aoi
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534771A
Other languages
English (en)
Japanese (ja)
Other versions
JP6351598B2 (ja
JP2015532096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062410 external-priority patent/WO2014055370A1/en
Publication of JP2015532096A publication Critical patent/JP2015532096A/ja
Publication of JP2015532096A5 publication Critical patent/JP2015532096A5/ja
Application granted granted Critical
Publication of JP6351598B2 publication Critical patent/JP6351598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015534771A 2012-10-01 2013-09-27 糖タンパク質を産生するための組成物および方法 Active JP6351598B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261708554P 2012-10-01 2012-10-01
US61/708,554 2012-10-01
PCT/US2013/062410 WO2014055370A1 (en) 2012-10-01 2013-09-27 Compostions and methods for producing glycoproteins

Publications (3)

Publication Number Publication Date
JP2015532096A JP2015532096A (ja) 2015-11-09
JP2015532096A5 true JP2015532096A5 (enExample) 2016-11-17
JP6351598B2 JP6351598B2 (ja) 2018-07-04

Family

ID=49354940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534771A Active JP6351598B2 (ja) 2012-10-01 2013-09-27 糖タンパク質を産生するための組成物および方法

Country Status (28)

Country Link
US (2) US20150259425A1 (enExample)
EP (1) EP2904092B1 (enExample)
JP (1) JP6351598B2 (enExample)
KR (1) KR102182885B1 (enExample)
CN (1) CN104797707A (enExample)
AU (1) AU2013327681B2 (enExample)
BR (1) BR112015007319B1 (enExample)
CA (1) CA2886753C (enExample)
CY (1) CY1119602T1 (enExample)
DK (1) DK2904092T3 (enExample)
EA (1) EA201590550A1 (enExample)
ES (1) ES2646594T3 (enExample)
HK (1) HK1207394A1 (enExample)
HR (1) HRP20171753T1 (enExample)
HU (1) HUE034896T2 (enExample)
IL (1) IL237916A0 (enExample)
IN (1) IN2015DN02630A (enExample)
LT (1) LT2904092T (enExample)
ME (1) ME02882B (enExample)
MX (1) MX366106B (enExample)
NO (1) NO2760138T3 (enExample)
PL (1) PL2904092T3 (enExample)
PT (1) PT2904092T (enExample)
RS (1) RS56641B1 (enExample)
SG (2) SG11201502339YA (enExample)
SI (1) SI2904092T1 (enExample)
SM (1) SMT201700588T1 (enExample)
WO (1) WO2014055370A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
JP2017537893A (ja) 2014-10-31 2017-12-21 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗cs1抗体および抗体薬結合体
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3400241B1 (en) 2016-01-06 2020-07-22 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
WO2017120359A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2017146646A1 (en) * 2016-02-22 2017-08-31 Agency For Science, Technology And Research Cell culture medium
EP3538151B1 (en) 2016-11-11 2024-06-26 Whitehead Institute for Biomedical Research Human plasma-like medium
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
CA3103610A1 (en) 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
JP7678761B2 (ja) * 2019-04-18 2025-05-16 モメンタ ファーマシューティカルズ インコーポレイテッド シアル化糖タンパク質
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2002066603A2 (en) * 2001-02-15 2002-08-29 Centocor, Inc. Chemically defined medium for cultured mammalian cells
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
DK1755659T3 (da) 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies

Similar Documents

Publication Publication Date Title
JP2015532096A5 (enExample)
HRP20171753T1 (hr) Pripravci i postupci za proizvodnju glikoproteina
SG10201909806SA (en) Production of t cell retargeting hetero-dimeric immunoglobulins
EA201900326A1 (ru) Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами
SG11201901495YA (en) Method for producing antibody fusion protein
EP2522724A4 (en) POLYPEPTIDE MODIFYING METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
JP2011525355A5 (enExample)
JP2012143232A5 (enExample)
EA202091422A1 (ru) Способ непрерывного производства продуктов на основе биспецифических антител
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
JP2013517776A5 (enExample)
IL310186B1 (en) Plasma kallikrein binding proteins
BR112015022529A2 (pt) meios de cultura de células e processos de produção de anticorpo
HRP20191409T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
MY169935A (en) "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ596595A (en) Method for orthopoxvirus production and purification
WO2010013947A3 (ko) 자연살해세포의 증식방법
JP2017508523A5 (enExample)
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
WO2015010118A3 (en) Transthyretin amyloid-selective and polyreactive catabodies
JP2017520531A5 (enExample)
MY184072A (en) Increasing virus like particle yield in plants